• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reactive capillary hemangiomas induced by camrelizumab in a patient with hepatocarcinoma.

作者信息

Zhang Xue, Wang Mengxin, Shi Bingjun

机构信息

Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital (First People's Hospital of Chongqing City), Chongqing, China.

Guizhou University of Traditional Chinese Medicine, Guiyang, China.

出版信息

Int J Dermatol. 2021 Oct;60(10):e409-e410. doi: 10.1111/ijd.15606. Epub 2021 May 26.

DOI:10.1111/ijd.15606
PMID:34036573
Abstract
摘要

相似文献

1
Reactive capillary hemangiomas induced by camrelizumab in a patient with hepatocarcinoma.卡瑞利珠单抗诱导肝癌患者发生的反应性毛细血管血管瘤
Int J Dermatol. 2021 Oct;60(10):e409-e410. doi: 10.1111/ijd.15606. Epub 2021 May 26.
2
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
3
Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent.抗PD-1药物卡瑞利珠单抗（SHR-1210）诱导的反应性毛细血管瘤。
Acta Oncol. 2019 Mar;58(3):388-389. doi: 10.1080/0284186X.2019.1567935. Epub 2019 Jan 30.
4
Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.病例报告：一种罕见的免疫相关不良反应：卡瑞利珠单抗诱导的肝海绵状血管瘤
Front Immunol. 2024 Apr 5;15:1387465. doi: 10.3389/fimmu.2024.1387465. eCollection 2024.
5
Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.病例报告：用 PD-1 抑制剂卡瑞利珠单抗成功治疗晚期肝癌。
Front Immunol. 2023 Jul 27;14:1221418. doi: 10.3389/fimmu.2023.1221418. eCollection 2023.
6
Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.卡瑞利珠单抗（SHR-1210）与阿帕替尼联合治疗的一名患者早期肝细胞癌完全缓解
Dig Liver Dis. 2019 Oct;51(10):1488-1490. doi: 10.1016/j.dld.2019.07.005. Epub 2019 Aug 7.
7
Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma.信迪利单抗诱发的复发性肝细胞癌患者筋膜炎症
Eur J Cancer. 2021 Sep;155:296-298. doi: 10.1016/j.ejca.2021.06.046. Epub 2021 Aug 4.
8
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.卡瑞利珠单抗治疗既往接受过治疗的晚期肝细胞癌患者的多中心、开放标签、平行分组、随机、Ⅱ期临床试验。
Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.
9
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps.前言：肝细胞癌：新兴治疗方法、药物靶点及基础知识空白
Expert Opin Investig Drugs. 2022 Apr;31(4):331. doi: 10.1080/13543784.2022.2046732. Epub 2022 Mar 2.
10
Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.口服反应性毛细血管血管瘤由 SHR-1210 诱发治疗非小细胞肺癌：病例报告及文献复习。
BMC Oral Health. 2021 Nov 2;21(1):559. doi: 10.1186/s12903-021-01901-9.

引用本文的文献

1
Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports.卡瑞利珠单抗治疗后非小细胞肺癌患者发生肝海绵状血管瘤：两例报告
Front Oncol. 2023 Aug 3;13:1221309. doi: 10.3389/fonc.2023.1221309. eCollection 2023.
2
Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.卡瑞利珠单抗引起的反应性皮肤毛细血管内皮细胞增生：16例病例报告
Indian J Dermatol. 2023 May-Jun;68(3):318-326. doi: 10.4103/ijd.ijd_343_22.
3
Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
安罗替尼改善了卡瑞利珠单抗诱导的反应性皮肤毛细血管内皮细胞增殖：一例报告
Transl Cancer Res. 2022 Aug;11(8):2940-2945. doi: 10.21037/tcr-22-426.